On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Howard A. Burris

ResearcherPublications, citations & collaboration network

Howard A. Burris is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Howard A. Burris have?

ScholarIQindexed works

Howard A. Burris has 1,154 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Howard A. Burris have?

ScholarIQcitation count

Howard A. Burris has 72,966 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Howard A. Burris?

ScholarIQh-index

Howard A. Burris has an h-index of 118 in OpenAlex.

What is the i10-index of Howard A. Burris?

ScholarIQi10-index

Howard A. Burris has an i10-index of 544 in OpenAlex.

What is the ORCID of Howard A. Burris?

ScholarIQorcid

The ORCID for Howard A. Burris is on the source record.

What is the OpenAlex record for Howard A. Burris?

ScholarIQopenalex

The OpenAlex for Howard A. Burris is on the source record.

What are the most-cited papers on Howard A. Burris?

ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
The Lancet. 20163,735 Citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
New England Journal of Medicine. 20162,037 CitationsOPEN ACCESS
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker, Jean MacFadyen, Tom Thurén, Brendan M Everett, Peter Libby, Robert J. Glynn, Paul M. Ridker, Alberto Lorenzatti, Henry Krum, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Jacques Genest, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, Wolfgang Köenig, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda
The Lancet. 20171,333 CitationsOPEN ACCESS
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Afshin Dowlati, Kimberly Blackwell, Bert H. O’Neil, P. Kelly Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve Mangum, Neil L. Spector
Journal of Clinical Oncology. 2005626 CitationsOPEN ACCESS
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel
The Lancet Oncology. 2016563 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account